SEO URLwww.firestrike.ai/deals/curevac-pfizer-acquisition-2026-2
acquisitionAnnounced · Jan 10, 2026biotechSource · Unverified ReportsArticle · Factual
Pfizer acquires CureVac
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$1.25B
Target
CureVac
Nasdaq: CVAC · Tuebingen, Baden-Wuerttemberg
Acquirer
Pfizer
Full Acquisition
Status
Pending
Pfizer agreed to acquire CureVac. Reported deal value: $1.25B. Status: Pending. Sector: biotech. Target headquarters context: Tuebingen, Baden-Wuerttemberg, Germany.
This page summarizes publicly available information about the transaction as of 2026-01-10. Figures and status may change as filings and press coverage update.
Following its acquisition by fellow mRNA specialist BioNTech for $1.25 billion , CureVac shares have been suspended from trading on the Nasdaq
Deal timeline
Announced
Jan 10, 2026 · ad-hoc-news.de
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotech with a reported deal value of $1.25B. Figures and status may change as sources update.
Sources: ad-hoc-news.de · Primary article · FireStrike proprietary index